share_log

Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $8

Benzinga ·  May 31, 2023 06:07

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $6 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment